SEC Info - Amag Pharmaceuticals, Inc. - ‘8-K’ for 5/8/20

SEC Info℠

Home

Help

Please Sign In

Amag Pharmaceuticals, Inc. – ‘8-K’ for 5/8/20 – ‘EX-16.1’

On: Monday, 5/11/20, at 7:18am ET · For: 5/8/20 · Accession #: 792977-20-42 · File #: 1-10865

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/11/20  Amag Pharmaceuticals, Inc.        8-K:2,4,9   5/08/20   15:2.9M

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     43K 
 3: EX-99.1     Miscellaneous Exhibit                               HTML    117K 
 4: EX-99.2     Miscellaneous Exhibit                               HTML     20K 
 2: EX-16.1     Letter re: Change in Certifying Accountant          HTML      8K 
12: R1          Cover Page                                          HTML     47K 
15: XML         IDEA XML File -- Filing Summary                      XML     13K 
13: XML         XBRL Instance -- amag-20200508_htm                   XML     22K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 6: EX-101.CAL  XBRL Calculations -- amag-20200508_cal               XML      7K 
 7: EX-101.DEF  XBRL Definitions -- amag-20200508_def                XML      9K 
 8: EX-101.LAB  XBRL Labels -- amag-20200508_lab                     XML     68K 
 9: EX-101.PRE  XBRL Presentations -- amag-20200508_pre              XML     34K 
 5: EX-101.SCH  XBRL Schema -- amag-20200508                         XSD     12K 
14: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
11: ZIP         XBRL Zipped Folder -- 0000792977-20-000042-xbrl      Zip    133K

‘EX-16.1’ — Letter re: Change in Certifying Accountant

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

<! C: C:

Document

Exhibit 16.1

May 11, 2020

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read the statements made by AMAG Pharmaceuticals, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of AMAG Pharmaceuticals, Inc. dated May 8, 2020. We agree with the statements concerning our Firm in such Form 8-K.

Very truly yours,

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

Attachment

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on:	5/11/20	10-Q
For Period end:	5/8/20
		List all Filings

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/15/20  Amag Pharmaceuticals, Inc.        S-8         9/15/20    3:84K                                    Toppan Merrill/FA

↑Top

Filing Submission 0000792977-20-000042 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)